Infigratinib phosphate is under clinical development by QED Therapeutics and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Infigratinib phosphate’s likelihood of approval (LoA) and phase transition for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) took place on 04 Mar 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Infigratinib phosphate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Infigratinib phosphate overview

Infigratinib phosphate (Truseltiq) is an anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Truseltiq is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.

Infigratinib phosphate (BGJ-398) is under development for the treatment of hematologic malignancies, advanced or metastatic cholangiocarcinoma, gastric cancer, adenocarcinoma of the gastroesophageal junction, prostate cancer, thyroid cancer, breast cancer, liver cancer, glioblastoma multiforme, progressive Low-Grade Glioma, urothelial carcinoma, hypochondroplasia and achondroplasia. The drug candidate is administered orally as a capsule. It targets pan-fibroblast growth factor receptor (FGFR). It was also under development for the treatment of solid tumors including recurrent glioblastoma multiforme (GBM), advanced gastrointestinal stromal tumor (GIST). It was under development for head and neck squamous cell carcinoma including nasopharyngeal cancer and muscle-invasive bladder cancer.

QED Therapeutics overview

QED Therapeutics, a biotechnology company focused on precision medicine for FGFR-driven disorders. The company is headquartered in United States.

Quick View Infigratinib phosphate LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Infigratinib phosphate
Administration Pathway
  • Oral
Therapeutic Areas
  • Musculoskeletal Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.